Charles River Laboratories International, Inc. (NYSE:CRL) Shares Sold by Geneva Capital Management LLC

Geneva Capital Management LLC lowered its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 13.7% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 12,790 shares of the medical research company's stock after selling 2,026 shares during the quarter. Geneva Capital Management LLC's holdings in Charles River Laboratories International were worth $2,361,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in the company. Empirical Finance LLC increased its position in Charles River Laboratories International by 4.2% in the third quarter. Empirical Finance LLC now owns 1,310 shares of the medical research company's stock worth $258,000 after purchasing an additional 53 shares during the last quarter. Fiduciary Financial Group LLC increased its position in Charles River Laboratories International by 3.9% during the fourth quarter. Fiduciary Financial Group LLC now owns 1,665 shares of the medical research company's stock valued at $310,000 after acquiring an additional 63 shares during the last quarter. Pinnacle Bancorp Inc. increased its position in Charles River Laboratories International by 52.0% during the fourth quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company's stock valued at $35,000 after acquiring an additional 65 shares during the last quarter. M&T Bank Corp increased its position in Charles River Laboratories International by 3.4% during the third quarter. M&T Bank Corp now owns 2,001 shares of the medical research company's stock valued at $394,000 after acquiring an additional 66 shares during the last quarter. Finally, Cornerstone Investment Partners LLC increased its position in Charles River Laboratories International by 3.7% during the fourth quarter. Cornerstone Investment Partners LLC now owns 1,940 shares of the medical research company's stock valued at $358,000 after acquiring an additional 69 shares during the last quarter. Hedge funds and other institutional investors own 98.91% of the company's stock.

Remove Ads

Wall Street Analyst Weigh In

A number of research analysts have weighed in on the stock. William Blair cut shares of Charles River Laboratories International from an "outperform" rating to a "market perform" rating in a research report on Wednesday, January 22nd. JPMorgan Chase & Co. cut their price objective on shares of Charles River Laboratories International from $175.00 to $165.00 and set a "neutral" rating on the stock in a research report on Thursday, February 20th. Robert W. Baird cut their price objective on shares of Charles River Laboratories International from $177.00 to $173.00 and set a "neutral" rating on the stock in a research report on Thursday, February 20th. Morgan Stanley cut their price objective on shares of Charles River Laboratories International from $220.00 to $184.00 and set an "equal weight" rating on the stock in a research report on Wednesday, February 5th. Finally, Citigroup raised shares of Charles River Laboratories International from a "sell" rating to a "neutral" rating and boosted their target price for the company from $155.00 to $175.00 in a research note on Tuesday, March 4th. One research analyst has rated the stock with a sell rating, fifteen have assigned a hold rating and one has given a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Hold" and an average target price of $198.36.

Insider Buying and Selling

In other Charles River Laboratories International news, EVP Joseph W. Laplume sold 4,400 shares of the stock in a transaction dated Thursday, February 20th. The shares were sold at an average price of $162.50, for a total transaction of $715,000.00. Following the completion of the sale, the executive vice president now directly owns 20,013 shares of the company's stock, valued at approximately $3,252,112.50. This represents a 18.02 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO James C. Foster purchased 6,075 shares of the firm's stock in a transaction on Thursday, February 20th. The shares were purchased at an average cost of $165.01 per share, with a total value of $1,002,435.75. Following the completion of the transaction, the chief executive officer now owns 183,639 shares of the company's stock, valued at approximately $30,302,271.39. The trade was a 3.42 % increase in their position. The disclosure for this purchase can be found here. 1.30% of the stock is owned by insiders.

Charles River Laboratories International Stock Up 4.1 %

NYSE:CRL traded up $6.93 during mid-day trading on Friday, reaching $176.20. The company's stock had a trading volume of 1,169,106 shares, compared to its average volume of 699,906. Charles River Laboratories International, Inc. has a 1 year low of $150.79 and a 1 year high of $274.77. The stock has a fifty day moving average of $169.15 and a 200-day moving average of $185.63. The firm has a market capitalization of $9.01 billion, a PE ratio of 1,174.68, a price-to-earnings-growth ratio of 4.54 and a beta of 1.45. The company has a quick ratio of 1.14, a current ratio of 1.41 and a debt-to-equity ratio of 0.65.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last released its quarterly earnings data on Wednesday, February 19th. The medical research company reported $2.66 earnings per share for the quarter, topping analysts' consensus estimates of $2.50 by $0.16. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The company had revenue of $1 billion during the quarter, compared to analyst estimates of $983.63 million. During the same period in the prior year, the firm earned $2.46 earnings per share. The firm's revenue for the quarter was down 1.1% compared to the same quarter last year. Equities research analysts forecast that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current year.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).